Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2047487320920754 http://scihub22266oqcxt.onion/10.1177/2047487320920754 32301349!7717238!32301349     free     free     free       Eur+J+Prev+Cardiol 2020 ; 27 (13): 1351-1353 Nephropedia Template TP {{tp|p=32301349|t=2020. Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia |pdf=|usr=}}{{32301349}} gab.com Text Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia JO: Eur J Prev Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=32301349 #FOAvip ? Twit Text FOAVip Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia ????Eur J Prev Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=32301349 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32301349 #FOAvip English Wikipedia <ref>{{Cite pmid|32301349}}</ref> Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia #MMPMID32301349 Rauch B Eur J Prev Cardiol 2020[Sep]; 27 (13): 1351-1353 PMID32301349show ga ? |*Betacoronavirus[MESH] |COVID-19[MESH] |Cardiovascular Diseases/complications/epidemiology/*prevention & control[MESH] |Coronavirus Infections/*complications/epidemiology[MESH] |Cost-Benefit Analysis[MESH] |Drug Therapy, Combination[MESH] |Humans[MESH] |Pandemics[MESH] |Platelet Aggregation Inhibitors/*therapeutic use[MESH] |Pneumonia, Viral/*complications/epidemiology[MESH] |SARS-CoV-2[MESH]Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibitio(epmc).pdf DeepDyve Pubget Overpricing